复合型抗菌药联合阿奇霉素对大叶性肺炎炎性指标的影响

Effects of Compound Antimicrobial Agents on the Inflammatory Factors of Lobar Pneumonia

目的:头孢哌酮钠舒巴坦钠与阿奇霉素联合应用对大叶性肺炎病人体内TNF-α、IL-6及HMGB1的变化影响及其临床疗效研究。方法:收集2012年11月至2015年3月期间到笔者所在医院就诊并诊断患有大叶性肺炎的病人随机平分成两组,其中A组与B组成员分别使用头孢哌酮钠舒巴坦钠+阿奇霉素和仅使用阿奇霉素进行大叶性肺炎对症治疗。通过炎性指标变化情况及对肺功能、不良反应的观察,分析两种药物联合应用对大叶性肺炎病人体内TNF-α、IL-6及HMGB1的变化影响和临床应用价值。结果:A组经联合用药治疗后相关炎症指标改善情况普遍优于B组;A组大叶性肺炎病人咳嗽、啰音及相关体征表现恢复速度快于B组,且A组病人在联合药物治疗后FEF和FEF50指标上的改善情况更为突出;而A组病人不良反应发生种类及例数、比率与B组却相差不大(P>0.05)。结论:头孢哌酮钠舒巴坦钠与阿奇霉素的联合应用可有效降低病人体内TNF-α、IL-6及HMGB1浓度水平,且其治疗效果较为突出,具有一定的应用价值。

Objective： To investigate the effect of lobar pneumonia patients＇ s TNF-α, IL-6 and HMGB1 by Cefoperazone sulbactam combined with azithromycin. Methods： The patents diagnosed as lobar pneumonia on November 2012 to March 2015 were randomly divided into two groups, The members of Group A were treated with cefoperazone sulbactam ＋ azithromycin and group B were only using azithromycin for treatment. By observing the changes in the indicators, analysis of the two drugs combined application of lobar pneumonia patient TNF-α, IL-6, HMGB1 and to explore the clinical application value. Results： Group A after combination therapy in the treatment of inflammatory markers improvement is generally superior to that in group B; group a lobar pneumonia cough, rales and signs performance recovery is faster than that of group B and combination drug therapy after FEF and fef50 index in the patients of a group to improve the situation more（the part not over） is one of the most outstanding; and group A patients with adverse reactions occurred types and case number, ratio of a and B differ little（P〉0.05）. Conclusion： Cefoperazone sulbactam in combination with azithromycin can reduce expression levels of TNF-α, IL-6 and HMGB1 and its treatment effect is more prominent, it has some clinical value.